Correlation Between Agilent Technologies and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Agilent Technologies and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Agilent Technologies and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Agilent Technologies and Monopar Therapeutics, you can compare the effects of market volatilities on Agilent Technologies and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Agilent Technologies with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Agilent Technologies and Monopar Therapeutics.
Diversification Opportunities for Agilent Technologies and Monopar Therapeutics
-0.61 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Agilent and Monopar is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding Agilent Technologies and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Agilent Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Agilent Technologies are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Agilent Technologies i.e., Agilent Technologies and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Agilent Technologies and Monopar Therapeutics
Taking into account the 90-day investment horizon Agilent Technologies is expected to generate 126.77 times less return on investment than Monopar Therapeutics. But when comparing it to its historical volatility, Agilent Technologies is 2.74 times less risky than Monopar Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Monopar Therapeutics is currently generating about 0.3 of returns per unit of risk over similar time horizon. If you would invest 1,696 in Monopar Therapeutics on September 4, 2024 and sell it today you would earn a total of 505.00 from holding Monopar Therapeutics or generate 29.78% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Agilent Technologies vs. Monopar Therapeutics
Performance |
Timeline |
Agilent Technologies |
Monopar Therapeutics |
Agilent Technologies and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Agilent Technologies and Monopar Therapeutics
The main advantage of trading using opposite Agilent Technologies and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Agilent Technologies position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.Agilent Technologies vs. Danaher | Agilent Technologies vs. Illumina | Agilent Technologies vs. IDEXX Laboratories | Agilent Technologies vs. Waters |
Monopar Therapeutics vs. Anebulo Pharmaceuticals | Monopar Therapeutics vs. Acrivon Therapeutics, Common | Monopar Therapeutics vs. Pmv Pharmaceuticals | Monopar Therapeutics vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Complementary Tools
Transaction History View history of all your transactions and understand their impact on performance | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |